Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Circulation

• Publication date

  2001-08-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/HC3301.092790PMID 11502709
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.

  2001cited by this paper
• Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.

  2001cited by this paper
• In vivo Octreotide Administration Acutely Reduces Exocrine Granule Size in the Human Pancreas

  2001cited by this paper
• Transcellular formation of thromboxane A(2) in mixed incubations of endothelial cells and aspirin-treated platelets strongly depends on the prostaglandin I-synthase activity.

  2000cited by this paper
• Selective cyclo‐oxygenase‐2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence

  2000cited by this paper
• Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.

  2000cited by this paper
• Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.

  1999cited by this paper
• Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

  1999cited by this paper
• Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function.

  1997cited by this paper
• Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

  1997cited by this paper
• The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis.

  1996cited by this paper
• Cytokine‐mediated induction of cyclo‐oxygenase‐2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide

  1995cited by this paper
• Eicosanoids and the gastrointestinal tract.

  1995cited by this paper
• The utility of excitatory amino acid (EAA) antagonists as analgesic agents. I. Comparison of the antinociceptive activity of various classes of EAA antagonists in mechanical, thermal and chemical nociceptive tests

  1994cited by this paper
• Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction.

  1994cited by this paper
• Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

  1994cited by this paper
• Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression.

  1993cited by this paper
• NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.

  1993cited by this paper
• High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury.

  1993cited by this paper
• Nonsteroidal anti-inflammatory drugs and peptic ulcer disease.

  1991cited by this paper
• Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.

  1990cited by this paper
• The eicosanoids and their biochemical mechanisms of action.

  1989cited by this paper
• Evidence for a bidirectional prostaglandin endoperoxide shunt between platelets and the bovine coronary artery.

  1989cited by this paper
• Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence.

  1988cited by this paper
• Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase).

  1988cited by this paper
• The endothelial cell as a metabolic and endocrine organ

  1987cited by this paper
• Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents.

  1980cited by this paper

• Vitis labruscana Bailey leaf extract improves vascular function markers including platelet aggregation: A randomized, double-blind, placebo-controlled trial.

  2025cites this paper
• Post-Infarction Inflammatory Alterations

  2021cites this paper
• Cardiovascular risk of nonsteroidal anti-inflammatory drugs in dialysis patients: a nationwide population-based study.

  2020cites this paper
• The quest for effective pharmacological suppression of neointimal hyperplasia.

  2020cites this paper
• Cardio-renal safety of non-steroidal anti-inflammatory drugs.

  2019cites this paper
• Endothelial cell transient receptor potential channel C5 (TRPC5) is essential for endothelium‐dependent contraction in mouse carotid arteries

  2019cites this paper
• Participation of COX-1 and COX-2 in the contractile effect of phenylephrine in prepubescent and old rats

  2017cites this paper
• Transmission pathways and mediators as the basis for clinical pharmacology of pain

  2016cites this paper
• New approaches to treating pain.

  2016cites this paper
• Celecoxib for the treatment of atherosclerosis

  2016cites this paper
• Anti-platelet therapy in small animal medicine.

  2016cites this paper
• Animal models of myocardial infarction: Mainstay in clinical translation.

  2016cites this paper
• Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation.

  2016cites this paper
• Proof-of-Concept Studies for Marker-Based Ultrasound Doppler Analysis of Microvascular Anastomoses in a Modified Large Animal Model

  2015cites this paper
• Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs).

  2015cites this paper
• Cyclooxygenase-2 : where are we in 2003 ? Cardiovascular risk and COX-2 inhibitors

  2015cites this paper
• Crystal Structures of mPGES-1 Inhibitor Complexes Form a Basis for the Rational Design of Potent Analgesic and Anti-Inflammatory Therapeutics.

  2015cites this paper
• Adiponectin signaling and metabolic syndrome.

  2014cites this paper
• Aspirin Modulates Innate Inflammatory Response and Inhibits the Entry of Trypanosoma cruzi in Mouse Peritoneal Macrophages

  2014cites this paper
• EFEITOS DA INIBIÇÃO DA COX-2 NO SISTEMA CARDIOVASCULAR DE CÃES

  2014influential citation
• ROLES OF INOSITOL DIPHOSPHATES IN DNA REPAIR AND EFFECTS OF ASPIRIN ANALOGUES ON OESOPHAGEAL CANCER

  2014cites this paper
• Non-steroidal anti-inflammatory drugs attenuate the vascular responses in aging metabolic syndrome rats

  2014cites this paper
• Cardiovascular pharmacogenetics of anti-thrombotic agents and non-steroidal anti-inflammatory drugs.

  2014cites this paper
• Genetic deletion of aquaporin-1 results in microcardia and low blood pressure in mouse with intact nitric oxide-dependent relaxation, but enhanced prostanoids-dependent relaxation

  2014cites this paper
• The biology behind the atherothrombotic effects of cigarette smoke

  2013cites this paper
• Current Perspectives in NSAID-Induced Gastropathy

  2013cites this paper
• Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.

  2013cites this paper
• Nabumetone

  2012cites this paper
• Cyclooxygenase-2-Derived Prostacyclin Regulates Arterial Thrombus Formation by Suppressing Tissue Factor in a SIRT1-Dependent-Manner Running title: Barbieri et al.; Prostacyclin regulates thrombosis via SIRT1

  2012cites this paper
• The effects of cyclosporine on platelet function and cyclooxygenase expression in normal dogs.

  2012cites this paper
• Novel Porcine Models of Myocardial Ischemia/Infarction – Technical Progress, Modified Electrocardiograms Validating, and Future Application

  2012cites this paper
• Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein.

  2012cites this paper
• Cyclooxygenase-2–Derived Prostacyclin Regulates Arterial Thrombus Formation by Suppressing Tissue Factor in a Sirtuin-1–Dependent-Manner

  2012cites this paper
• Antagonism of the antithrombotic and anti‐atherosclerotic actions of aspirin by rofecoxib in the cholesterol‐fed rabbit

  2011cites this paper
• Effects of meloxicam and etoricoxib on blood pressure andvascular reactivity in rats

  2011cites this paper
• Adiponectin and hypertension.

  2011cites this paper
• Celecoxib in the Treatment of Osteoarthritis

  2010cites this paper
• The influence of constitutive COX-2 in smooth muscle tissue on the contractile effect of phenylephrine in the rat abdominal aorta.

  2010cites this paper
• NSAID Action and the Foundations for Cardiovascular Toxicity

  2010cites this paper
• Emotion recollected in tranquility: lessons learned from the COX-2 saga.

  2010cites this paper
• Pathophysiology of Cyclooxygenases in Cardiovascular Homeostasis

  2010cites this paper
• Use of Nonsteroidal Anti-Inflammatory Drugs in Patients With Cardiovascular Disease: A Cautionary Tale

  2010cites this paper
• Chapter 150 – Prostaglandin Mediators

  2010cites this paper
• Drug designing and docking efficacy assessment of halogen substituted aspirin

  2010cites this paper
• Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drugs: Gastrointestinal-Sparing Potential Drugs

  2009cites this paper
• Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2.

  2009cites this paper
• The Journal of Toxicological Sciences

  2009cites this paper
• Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.

  2009cites this paper
• Vascular biology of eicosanoids and atherogenesis

  2009cites this paper
• Renal and cardiovascular characterization of COX-2 knockdown mice.

  2009cites this paper
• Cyclooxygenase-2–Derived Prostaglandin F2&agr; Mediates Endothelium-Dependent Contractions in the Aortae of Hamsters With Increased Impact During Aging

  2009cites this paper
• Enhanced cyclooxygenase 2‐mediated vasodilatation in coronary arteries from insulin resistant obese Zucker rats

  2009cites this paper
• Cardiovascular Effects of Anesthetics, Sedatives, Postoperative Analgesic Agents, and Other Pharmaceuticals

  2009cites this paper
• Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1

  2009cites this paper
• Cyclooxygenase-2-Linked Attenuation of Hypoxia-Induced Pulmonary Hypertension and Intravascular Thrombosis

  2008cites this paper
• Microsomal Prostaglandin E 2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction

  2008cites this paper
• Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus.

  2008cites this paper
• Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis.

  2008cites this paper
• Cyclooxygenase-2 pathway as a potential therapeutic target in diabetic peripheral neuropathy.

  2008cites this paper
• Cyclooxygenase products and atherosclerosis.

  2008cites this paper
• Prostanoid and isoprostanoid pathways in atherogenesis.

  2008cites this paper
• Microsomal Prostaglandin E2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction

  2008cites this paper
• [The safety of COX-2 inhibitors].

  2008cites this paper
• Non-Steroidal Antiinflammatory Drug Gastroenteropathy

  2008cites this paper
• The Effect of Cyclooxygenase-2 Inhibition on Renal Hemodynamic Function in Humans With Type 1 Diabetes

  2008cites this paper
• Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?

  2007cites this paper
• The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame

  2007influential citation
• COX-2 inhibitors and cardiovascular risk.

  2007cites this paper
• fl RENAL EFFECTS OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS IN RAT : A LIGHT AND ELECTRON MICROSCOPIC STUDY

  2007cites this paper
• Rational Use of Analgesic and Antiinflammatory Drugs

  2007cites this paper
• Aspirin and COX-2 inhibitor nimesulide potentiate adrenergic contractions of human gastroepiploic artery.

  2007cites this paper
• Effects of the Cyclooxygenase Inhibition on Canine Coronary Artery Blood Flow and Thrombosis

  2007influential citation
• Antagonism of thromboxane receptors by diclofenac and lumiracoxib

  2007cites this paper
• COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management.

  2007cites this paper
• Modulation of prostaglandin activity, part 1: Prostaglandin inhibition in the management of nonrheumatologic diseases: Immunologic and hematologic aspects

  2007cites this paper
• Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.

  2007cites this paper
• Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis

  2006cites this paper
• Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.

  2006cites this paper
• Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation.

  2006cites this paper
• yclooxygenase-2 Inhibitors Enhance hear Stress-Induced Platelet Aggregation

  2006cites this paper
• Cyclooxygenase inhibition and atherothrombosis.

  2006cites this paper
• Prothrombotic potential of NSAID in ischemic heart disease.

  2006cites this paper
• Cyclooxygenase-2 inhibitors: a painful lesson.

  2006cites this paper
• Increased Cyclooxygenase-2 Expression and Prostaglandin-Mediated Dilation in Coronary Arterioles of Patients With Diabetes Mellitus

  2006cites this paper
• Pharmacologic inhibition of platelet vWF-GPIbα interaction prevents coronary artery thrombosis

  2006cites this paper
• Selective COX-2 inhibitors and risk of thromboembolic events – regulatory aspects

  2006cites this paper
• Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal

  2006cites this paper
• Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs?

  2006cites this paper
• The pharmacology of selective inhibition of COX-2

  2006cites this paper
• Arthritis medicines and cardiovascular events--"house of coxibs".

  2005cites this paper
• Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse.

  2005cites this paper
• Low Direct Cytotoxicity and Cytoprotective Effects of Nitric Oxide Releasing Indomethacin

  2005cites this paper
• A contribution to genetic etiology of complex regional pain syndrome type I (algodystropy syndrome) based on quantitative analysis of digitopalmar dermatoglyphics in sixty men.

  2005cites this paper
• Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

  2005cites this paper
• Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products

  2005cites this paper
• The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief.

  2005cites this paper
• Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?

  2005cites this paper
• The Antithrombotic Effect of Melagatran in Combination With Clopidogrel and/or Aspirin (carotid artery primary thrombosis study)

  2005cites this paper
• Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study.

  2005cites this paper
• Nitric oxide releasing derivatives of tolfenamic acid with anti-inflammatory activity and safe gastrointestinal profile.

  2005cites this paper